Facebook Pixel

Roche Breast Cancer Pill Fails To Help Older Women

Rate This

CHICAGO, May 31 (Reuters) - Swiss drugmaker Roche Holding AG's (ROG.VX: Quote, Profile, Research) oral chemotherapy drug Xeloda, or capecitabine, proved inferior to standard chemotherapy in treating older women with early stage breast cancer, a study released on Saturday at a major meeting of oncology specialists found.

Researchers had thought the oral pill, if effective, could be a gentler alternative to standard chemotherapy after surgery in women older than 65 -- an age group typically underrepresented in clinical trials.

"What we found was standard therapy was superior," said the study's lead author, Dr. Hyman Muss of the University of Vermont's College of Medicine. "These were rather surprising numbers."

Add a CommentComments

There are no comments yet. Be the first one and get the conversation started!

Enter the characters shown in the image.
By submitting this form, you agree to EmpowHER's terms of service and privacy policy

Breast Cancer

Get Email Updates

Related Checklists

Breast Cancer Guide


Have a question? We're here to help. Ask the Community.


Health Newsletter

Receive the latest and greatest in women's health and wellness from EmpowHER - for free!